Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    21606412 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
Conditions: Lymphoma;   Cancer;   Thyroid Carcinoma
Intervention: Drug: XL184

Indicates status has not been verified in more than two years